Promise Bio receives 8.3 million US dollars in seed funding

Tel Aviv startup Promise Bio moves out of stealth mode to enable precision medicine for autoimmune diseases with an AI-powered platform

Tel Aviv, December 16, 2024 - Israeli startup Promise Bio has announced its market entry with a successful seed funding round of $8.3 million. The round is led by Awz Ventures, with additional support from the venture seed track of AION Labs, funded by AstraZeneca and Pfizer.

AI against autoimmune diseases

Promise Bio is revolutionizing the treatment of autoimmune diseases through a platform that combines epiproteomics and artificial intelligence (AI). The aim is to identify predictive biomarkers and develop patient-specific therapies.

Today's drugs often only work in 30-40% of patients with autoimmune diseases. Our platform offers a data-driven solution to improve these chances of success

Ronel Veksler, co-founder and CEO of Promise Bio

The PROMISE platform (Protein Modification Integrated Search Engine) is based on findings from research at the Weizmann Institute and enables comprehensive analysis of protein modifications. These modifications provide deeper insights into disease mechanisms and help to develop customized therapies.

What makes the platform special?

• Broad protein modification analysis: The platform can identify multiple post-translational modifications (PTMs) from mass spectrometry data without additional laboratory steps.
• Integration of AI: Machine learning approaches decipher complex data patterns, enabling more accurate prediction of therapy outcomes.
• Scalability: Analyzing large amounts of data creates the world's largest PTM database - a valuable tool for the development of future drugs.

The changes that proteins undergo during a disease provide us with crucial information about disturbances in immune regulation. With our platform, we can visualize these changes in HD quality.

Dr. Assaf Kacen, co-founder and CTO of Promise Bio

Strategic partnerships

Promise Bio's technology has the potential to fundamentally change the treatment of immune diseases. The investment in this platform is a milestone for precision medicine.

Mati Gill, CEO of AION Labs

The collaboration with AstraZeneca and Pfizer goes beyond financial support: it provides access to global networks, industry knowledge and integration of the platform into pharmaceutical development processes.